• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • DMF (Drug Master Filing) – Pharmaceutical Products
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • CML (China Manufacture Licence) – Pressure vessels
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Company Profile
    • Partners
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Information
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • DMF
      • CCC
      • Pressure Vessels
    • Publications
    • Brochure
    • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Draft Regulation for Drug-Device Combination Product Registration in China

Draft Regulation for Drug-Device Combination Product Registration in China

Friday, 22 January 2021 / Published in Medical Device, NMPA Registration in China

Draft Regulation for Drug-Device Combination Product Registration in China

On January 12, the National Medical Products Administration (NMPA) announced (No.6-2021) the amendment regulation (draft) for the registration of drug-device combination products.

The new draft refines the 2009 version with 8 major changes whilst the definition of drug-device combination products remains unchanged, the purpose of the changes is to clarify the registration requirements and categorization method of different drug-device combination products.

The new draft proposed to remove the following clause 6 from the original regulation:

“Applications for combination products, importing to China for the first time, will not be accepted for the following reasons:

–           The market approval of the product has not been obtained from the exporting country

–           The drug contained in the product has not obtained the registration approval from China or the market approval from the country of origin”

The draft also provided the following reasons for removing clause 6:

–           Some of the drugs contained in the combination products may not be regulated in the exporting country hence it could be impossible to obtain the required marketing approval

–           Even if the drug has obtained the marketing approval from the exporting country, the combination product may contain the raw material(s) of the drug with the adoption of a different production process, dosage, intended use etc. from the original drug itself

As a solution, applicants are suggested to refer to the following clause 2 (updated in the new draft) for submitting the appropriate market approval certificate:

–           If the combination product intends to achieve a therapeutic effect on the patient, the applicant shall meet the registration requirements of a medical device in China. Otherwise, if the combination product intends to achieve a drug effect on the patient, the applicant shall meet the registration requirements of a drug product in China.

In addition, the NMPA will implement a new set of technical review guidelines soon for the applicants to follow when registering their products in future.

The NMPA launched a public consultation to solicit comments for the draft. Stay tuned for more updates and let us know if you would like to share your opinions with us before the consultation period ends on January 26, 2021.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Combination Products, Drug - Medical Device Combination

What you can read next

NMPA Guidelines to Successfully Register Coronavirus Protection Supplies for Sale in China
Updates on the Clinical Trial Exemption List for Medical Devices and IVDs
New Functions of the Technical Review Consultation Platform

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Drug Master Filing
      • Health Food
      • Medical Device
    • RoHS
  • Publications
  • Seminars
  • Webinars

Recent Posts

  • Updates on the Medical Device Classification Catalogue in China

    On December 31, 2020, the NMPA announced (No.14...
  • Cisema Partners with Advamed

    Cisema is delighted to announce it is now an as...
  • Guidelines for Sampling Testing on Organic Foods

    On December 4, 2020, the CNCA (Certification an...
  • Draft of Prohibited List and Existing List of Cosmetic Ingredients Announced

    On January 22, 2021, the NIFDC (China National ...
  • Guideline and Standard Update for Medical Devices & IVDs in January and February 2021

    China Regulatory Guidelines Issued / Updated Th...

Archive

Cisema

With nine locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Events
  • News & Information
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2019 Cisema. All rights reserved.

TOP